BACKGROUND: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-breaks. These kinds of damage lead to the activation of PARP1, a first-line enzyme in DNA-damage response pathways. We hypothesized that PARP1 targeting could perpetuate trabectedin-induced DNA damage in tumor cells leading finally to cell death. METHODS: We investigated trabectedin and PARP1 inhibitor synergism in several tumor histotypes both in vitro and in vivo (subcutaneous and orthotopic tumor xenografts in mice). We searched for key determinants of drug synergism by comparative genomic hybridization (aCGH) and gene expression profiling (GEP) and validated their functional role. RESULTS: Trabectedin activated PARP1 enzyme and the combination with PARP1 inhibitors potentiated DNA damage, cell cycle arrest at G2/M checkpoint and apoptosis, if compared to single agents. Olaparib was the most active PARP1 inhibitor to combine with trabectedin and we confirmed the antitumor and antimetastatic activity of trabectedin/olaparib combination in mice models. However, we observed different degree of trabectedin/olaparib synergism among different cell lines. Namely, in DMR leiomyosarcoma models the combination was significantly more active than single agents, while in SJSA-1 osteosarcoma models no further advantage was obtained if compared to trabectedin alone. aCGH and GEP revealed that key components of DNA-repair pathways were involved in trabectedin/olaparib synergism. In particular, PARP1 expression dictated the degree of the synergism. Indeed, trabectedin/olaparib synergism was increased after PARP1 overexpression and reduced after PARP1 silencing. CONCLUSIONS: PARP1 inhibition potentiated trabectedin activity in a PARP1-dependent manner and PARP1 expression in tumor cells might be a useful predictive biomarker that deserves clinical evaluation.

PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models

PIGNOCHINO, YMERA;D'AMBROSIO, LORENZO;ALIBERTI, Sandra;PALESANDRO, ERICA;BOCCONE, Paola;GALIZIA, DANILO;MIANO, Sara;CHIABOTTO, GIULIA;NAPIONE, Lucia;SANGIOLO, Dario;PASINI, Barbara;CHIORINO, Giovanna;AGLIETTA, Massimo;
2017

Abstract

BACKGROUND: Enhancing the antitumor activity of the DNA-damaging drugs is an attractive strategy to improve current treatment options. Trabectedin is an isoquinoline alkylating agent with a peculiar mechanism of action. It binds to minor groove of DNA inducing single- and double-strand-breaks. These kinds of damage lead to the activation of PARP1, a first-line enzyme in DNA-damage response pathways. We hypothesized that PARP1 targeting could perpetuate trabectedin-induced DNA damage in tumor cells leading finally to cell death. METHODS: We investigated trabectedin and PARP1 inhibitor synergism in several tumor histotypes both in vitro and in vivo (subcutaneous and orthotopic tumor xenografts in mice). We searched for key determinants of drug synergism by comparative genomic hybridization (aCGH) and gene expression profiling (GEP) and validated their functional role. RESULTS: Trabectedin activated PARP1 enzyme and the combination with PARP1 inhibitors potentiated DNA damage, cell cycle arrest at G2/M checkpoint and apoptosis, if compared to single agents. Olaparib was the most active PARP1 inhibitor to combine with trabectedin and we confirmed the antitumor and antimetastatic activity of trabectedin/olaparib combination in mice models. However, we observed different degree of trabectedin/olaparib synergism among different cell lines. Namely, in DMR leiomyosarcoma models the combination was significantly more active than single agents, while in SJSA-1 osteosarcoma models no further advantage was obtained if compared to trabectedin alone. aCGH and GEP revealed that key components of DNA-repair pathways were involved in trabectedin/olaparib synergism. In particular, PARP1 expression dictated the degree of the synergism. Indeed, trabectedin/olaparib synergism was increased after PARP1 overexpression and reduced after PARP1 silencing. CONCLUSIONS: PARP1 inhibition potentiated trabectedin activity in a PARP1-dependent manner and PARP1 expression in tumor cells might be a useful predictive biomarker that deserves clinical evaluation.
Apr 28;16
1
1
15
http://www.molecular-cancer.com/start.asp
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410089/
Bone and soft tissue sarcomas; DNA-damaging agents; Drug synergism; Olaparib; PARP1 inhibitors; Predictive biomarkers; Trabectedin; Molecular Medicine; Oncology; Cancer Research
Pignochino, Ymera; Capozzi, Federica; D'Ambrosio, Lorenzo; Dell'Aglio, Carmine; Basiricò, Marco; Canta, Marta; Lorenzato, Annalisa; Vignolo Lutati, Francesca; Aliberti, Sandra; Palesandro, Erica; Boccone, Paola; Galizia, Danilo; Miano, Sara; Chiabotto, Giulia; Napione, Lucia; Gammaitoni, Loretta; Sangiolo, Dario; Benassi, Maria Serena; Pasini, Barbara; Chiorino, Giovanna; Aglietta, Massimo; Grignani, Giovanni
File in questo prodotto:
File Dimensione Formato  
Mol Cancer 2017.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 5.83 MB
Formato Adobe PDF
5.83 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1636100
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 40
social impact